By Professor David Goldstein

Journal articles

Huang X; Butow PN; Meiser B; Goldstein D, 1999, 'Attitudes and information needs of Chinese migrant cancer patients and their relatives', Australian and New Zealand Journal of Medicine, 29, pp. 207 - 213, http://dx.doi.org/10.1111/j.1445-5994.1999.tb00685.x

Bishop JF; Dewar J; Toner GC; Smith J; Tattersall MHN; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J; Canetta R, 1999, 'Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer', Journal of Clinical Oncology, 17, pp. 2355 - 2364, http://dx.doi.org/10.1200/jco.1999.17.8.2355

Davis AJ; Goldstein D; Milliken S, 1998, 'Long term follow-up of CEOP in the treatment of HIV related non- Hodgkin's lymphoma (NHL)', Australian and New Zealand Journal of Medicine, 28, pp. 28 - 32, http://dx.doi.org/10.1111/j.1445-5994.1998.tb04455.x

Newell ME; Milliken ST; Goldstein D; Lewis CR; Boyle MJ; Dolan G; Ryan S; Cooper DA; boyle , 1998, 'A phase 2 study of liposomal doxorubicin in the treatment of AIDS-related Kaposi¿s sarcoma', Australian and New Zealand Journal of Medicine, pp. 777 - 783

Goldstein D; Hertzog P; Tomkinson E; Couldwell D; Mccarville S; Parrish S; Cunningham PH; Newell ME; Owens M; Cooper DA, 1998, 'Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification', Journal of Infectious Diseases, 178, pp. 856 - 861

Bishop JF; Dewar J; Toner GC; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J, 1997, 'Paclitaxel as first-line treatment for metastatic breast cancer', ONCOLOGY, 11, pp. 19 - 23

Goldstein D; Pillay P; Hayman J; Leydman M, 1997, 'Association of hypercalcaemia, PTHrP expression and disease progression in a woman with primary squamous cell carcinoma of the breast.', Pathologe, pp. 317 - 319

Goldstein D; Douglas JR; Penny R; Matthews JP; Laidlaw CR; Gibson K; Bradstock KF; Wolf M, 1997, 'Australian leukaemia study group myeloma II: A randomised trial of intensive combination chemotherapy with or without interferon in patients with myeloma.', British Journal Haematology, pp. 38 - 45

Joshua D; Penny R; Matthews JP; Laidlawcr ; Gibson K; Bradstock KF; Wolf M; Goldstein D, 1997, 'Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive comBination chemotherapy with or without interferon in patients with myeloma', British Journal of Haematology, pp. 38 - 45

Goldstein D; Butow P; Tattersall MH, 1997, 'Communication with cancer patients in culturally diverse Societies.', Annals of the New York Academy of Sciences, pp. 317 - 329

Goldstein D; Wolley I; Collett J, 1997, 'Diffuse alveolar damage following a singel adminstration of a cyclophosphamide containing chemotherapy regimen.', Australian and New Zealand Journal of Medicine, pp. 605 - 606

Goldstein D; Bishop J; Dewar J; Tattersall MH; Smith JS; Olver IN; Ackland S; Kennedy I; Toner GC; Gurney H; Walpole E; Levi J; Stephenson J, 1997, 'Paclitaxel as first line treatment for metastatic breast cancer.', Oncology, pp. 17 - 19

Padiglione A; Goldstein D; Law MG; Hoy JF; Kaldor JM; Mijch AM, 1997, 'Prognosis of Kaposi`s sarcoma as an initial and later AIDS associated illness', Annals of Oncology, pp. 871 - 875

Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R, 1996, 'Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer', Urology, 48, pp. 957 - 962, http://dx.doi.org/10.1016/S0090-4295(96)00375-5

Millar JL; Goldstein D; Gelmon KA, 1996, '5.14 HIV and Kaposi's sarcoma', Medical Journal of Australia, 164, pp. 539 - 542, http://dx.doi.org/10.5694/j.1326-5377.1996.tb122167.x

Boyle MJ; Goldstein DA; Frazer IH; Sculley TB, 1996, 'How HIV promotes malignancies', Medical Journal of Australia, 164, pp. 230 - 232, http://dx.doi.org/10.5694/j.1326-5377.1996.tb94147.x

Goebel F; Goldstein D; Goos M; Jablonowski H; Stewart JS, 1996, 'Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi`s sarcoma', British Journal of Cancer, 73, pp. 989 - 994, http://dx.doi.org/10.1038/bjc.1996.193

Morton J; Taylor K; Bunce I; Eliadis P; Rentoul A; Moore D; Kelly C; Wright S; Bashford J; Rodwell R; Rooney K; Mulligan S; Firkin F; Dodds A; Parkin J; Lowenthal R; Kimber R; Frost T; Grigg A; Goldstein D; Stone J; Lee N, 1996, 'High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma', British Journal of Haematology, 95, pp. 110 - 115, http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1868.x

Goldstein D, 1996, 'HIV associated malignancies', Hematology Reviews and Communications, 9, pp. 275 - 283

Dear AE; Goldstein D; Hayman JA, 1996, 'Malignant pulmonary lymphoid disease: Case reports illustrating anatomical pattern of disease as a prognostic marker', Pathology, 28, pp. 20 - 24, http://dx.doi.org/10.1080/00313029600169443

Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D, 1996, 'Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma', Annals of Oncology, 7, pp. 1029 - 1036, http://dx.doi.org/10.1093/oxfordjournals.annonc.a010495

Millward MJ; Bishop JF; Friedlander M; Levi JA; Goldstein D; Olver IN; Smith JG; Toner GC; Rischin D; Bell DR, 1996, 'Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer', Journal of Clinical Oncology, 14, pp. 142 - 148, http://dx.doi.org/10.1200/JCO.1996.14.1.142

Nirenberg A; Meikle GR; Goldstein D; Meikle RG, 1995, 'Metastatic carcinoma infiltrating lung mimicking BOOP', Australasian Radiology, 39, pp. 405 - 407, http://dx.doi.org/10.1111/j.1440-1673.1995.tb00323.x

Pryor K; Goddard JD; Goldstein D; Stricker PD; Russell PJ; Golovsky D; Penny R, 1995, 'Bacillus Calmette-Guerein (BCG) enhances mobocyte-and lymphocyte-mediated bladder tumour cell killilng', British Journal of Cancer, 71, pp. 801 - 807, http://dx.doi.org/10.1038/bjc.1995.155

Dear A; Goldstein D; Salem H, 1995, 'pulmonary chronic lymphocytic leukaemia: difficulty in establishing a tissue diagnosis', European Journal of Haematology, pp. 130 - 133

FRIEDLANDER M; LEWIS C; GOLDSTEIN D, 1994, 'UNTITLED', MEDICAL JOURNAL OF AUSTRALIA, 161, pp. 638 - 638, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PT68600027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tindall B; Forde S; Ross MW; Goldstein D; Barker S; Cooper DA, 1994, 'Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine', Patient Education and Counseling, 24, pp. 261 - 266, http://dx.doi.org/10.1016/0738-3991(94)90069-8

Kaldor J; Elford J; Grulich A; Goldstein D, 1994, 'HIV AIDS and cancer', Cancer Forum, 18, pp. 3 - 11

Tindall B; Forde S; Goldsten D; Ross MW; Cooper DA, 1994, 'Sexual dysfunction in advanced HIV disease', AIDS Care, 6, pp. 105 - 107, http://dx.doi.org/10.1080/09540129408258030

Mackintosh JF; Friedlander M; Lewis C; Goldstein D; Herrmann RP; Kearsley JH, 1994, 'Wanted: Guidelines for 'palliative' anti-cancer drug use [3]', Medical Journal of Australia, 161, pp. 638 - 639, http://dx.doi.org/10.5694/j.1326-5377.1994.tb127659.x

GOLDSTEIN D; MILLIKEN S NM; LEWIS C; HOY J; THOMSON B; DOLAN G; RYAN S; SARR A; COOPER DA, 1994, 'FILGRASTIM (r-metHuG-CSF, Amgen), CEOP AND ANTIRETROVIRAL THERAPY IN HIV- RELATED NON-HODGKINS LYMPHOMA (NHL)', AIDS, 8, pp. S46 - S46, http://dx.doi.org/10.1097/00002030-199411004-00179

D G; E T; D C; H G; M N; P H; M O; S M; S P; D H; D C, 1994, 'PHASE I A/B TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER IN ASYMPTOMATIC HTV POSITIVE INDIVIDUALS', AIDS, 8, pp. S14 - S14, http://dx.doi.org/10.1097/00002030-199411004-00054

Tindall B; Carr A; Goldstein D; Penny R; Cooper DA, 1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020

Lewis CR; Segelov E; Goldstein D; Friedlander ML, 1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x

Nolten WE; Goldstein D; Lindstrom M; Mckenna MV; Carlson IH; Trump DL; Schiller J; Borden EC; Ehrlich EN, 1993, 'Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients', Journal of Interferon Research, 13, pp. 349 - 357, http://dx.doi.org/10.1089/jir.1993.13.349

Gibson DFC; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC, 1993, 'Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse', Breast Cancer Research and Treatment, 25, pp. 141 - 150, http://dx.doi.org/10.1007/BF00662139

GOLDSTEIN D; KAUFMANN M, 1992, 'NOVEL APPROACHES TO THE MANAGEMENT OF GYNECOLOGIC MALIGNANCIES - CHAIRMENS PREFACE - PROCEEDINGS OF A SATELLITE SYMPOSIUM HELD IN CAIRNS, AUSTRALIA, ON 22 SEPTEMBER 1991', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2, pp. 1 - 1, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992KF21500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Smalley RV; Goldstein D; Bulkowski D; Hannon C; Buchler D; Knudsen C; Tuttle RL, 1992, 'A phase II study of crisnatol mesylate in patients with ovarian carcinoma', Investigational New Drugs, 10, pp. 107 - 112, http://dx.doi.org/10.1007/BF00873127

Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC, 1992, 'Absence of Biological Effects of Orally Administered Interferon-βser', Journal of Interferon Research, 12, pp. 411 - 413, http://dx.doi.org/10.1089/jir.1992.12.411

Greiner JW; Guadagni F; Goldstein D; Smalley RV; Borden EC; Simpson JF; Molinolo A; Schlom J, 1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746

Greiner JW; Guadagni F; Borden EC; Ritts RE; Goldstein D; LoBuglio AF; Schlom J, 1992, 'EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA', Journal of Immunotherapy, 11, pp. 126 - 126, http://dx.doi.org/10.1097/00002371-199202000-00021

Greiner JW; Guadagni F; Goldstein D; Borden EC; Ritts RE; Witt P; LoBuglio AF; Saleh MN; Schlom J, 1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163

Goldstein D; Lewis C, 1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019

Goldstein D; O'Leary M; Mitchen J; Borden EC; Wilding G, 1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5

Sosman JA; Hank JA; Moore KH; Borchert A; Schell K; Kohler PC; Goldstein D; Bechhofer R; Storer B; Albertini MR; Leung PE; Levitt D; Sondel PM, 1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798

Robinson SP; Goldstein D; Witt PL; Borden EC; Jordan VC, 1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781

Goldstein D; Cheuvart B; Trump DL; Shiraki M; Comis RL; Tormey DC; Harris JE; Borden EC, 1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology: Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011

Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY, 1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521

GOLDSTEIN D; SOSMAN JA; HANK JA; WEILHILLMAN G; MOORE KH; BORCHERT A; BECHHOFER R; STORER B; KOHLER PC; LEVITT D; SONDEL PM, 1989, 'REPETITIVE WEEKLY CYCLES OF INTERLEUKIN-2 - EFFECT OF OUTPATIENT TREATMENT WITH A LOWER DOSE OF INTERLEUKIN-2 ON NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED KILLER ACTIVITY', CANCER RESEARCH, 49, pp. 6832 - 6839, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1989CA66300061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Goldstein D; Sielaff KM; Stores BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC, 1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061

Back to profile page